매크로 컨텍스트

테마

Biosimilars

핵심 동인

  • Keytruda biosimilar development progress
  • Celltrion Healthcare merger secures proprietary distribution margins
  • U.S. IRA drug price negotiation → accelerates biosimilar adoption
  • Global biosimilar market growing 15%+ annually

리스크

  • Keytruda biosimilar FDA approval delay
  • Losing to originator pharma rebate strategies
  • Celltrion Healthcare merger integration risk
  • Indian biosimilar companies price competition

애널리스트 컨센서스

최저 170,000 KRW최고 290,000 KRW
현재가컨센서스 목표가

2026. 6. 16. 기준

증권사애널리스트목표가투자의견
투자 기간: 12개월

모니터링 트리거

핵심 지표

  • Keytruda biosimilar clinical progress
  • U.S. biosimilar revenue growth rate
  • Celltrion Healthcare merger integration synergies
  • Operating margin trend

리뷰 트리거

  • Keytruda biosimilar clinical failure
  • U.S. biosimilar revenue declines 10%+ QoQ
  • Merger integration costs exceed expectations

무효화 조건

  • Keytruda biosimilar FDA rejection
  • Biosimilar adoption rate significantly below expectations
  • Complete failure of proprietary drug pipeline

노트 타임라인

진입
2026. 2. 25. · NewMoneyMoves AI

Post Celltrion Healthcare merger, proprietary distribution margin improvement confirmed. Keytruda biosimilar targets the world's largest blockbuster drug, with revenue level-up expected upon success.

Related ETFs

ETFs covering the same theme as 068270.KS — alternatives when direct holding is constrained or diversification is preferred

All ETFs

Comments

생성: 2026. 2. 25.수정: 2026. 2. 25.가격 기준: 2026. 6. 16.